|Day's Range||17.18 - 17.70|
|52 Week Range||11.20 - 42.25|
|PE Ratio (TTM)||-4.26|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
An increase in EBITDA guidance doesn't necessarily mean this company's back on track.
Valeant and Gilead Sciences' are arguably cheap stocks, but big questions remain that still make them risky to buy.
Billionaires appear to have focused on drug stocks that were mired in debt in Q1.